Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ponatinib - Takeda

Drug Profile

Ponatinib - Takeda

Alternative Names: AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; Iclusig; Ponatinib hydrochloride

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer ARIAD Pharmaceuticals; Dana-Farber Cancer Institute; Fundacion CRIS de Investigacion para Vencer el Cancer; Incyte Corporation; Massachusetts General Hospital; Mayo Clinic; National Cancer Institute (USA); Otsuka Pharmaceutical; University of Birmingham; University of Colorado at Denver
  • Class Antineoplastics; Benzamides; Imidazoles; Piperazines; Pyridazines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Acute myeloid leukaemia; Biliary cancer; Gastrointestinal stromal tumours; Lung cancer; Squamous cell cancer; Thyroid cancer
  • Phase I/II Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Jun 2020 Interim efficacy and safety data from the phase II OPTIC trial in Chronic myeloid leukaemia released by Takeda
  • 29 May 2020 Additional adverse events data from the phase II OPTIC trial in Chronic myeloid leukaemia presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 29 May 2020 Additional adverse events data from the phase II PACE trial in Chronic myeloid leukemia and Acute lymphoblastic Leukemia presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top